WO1994017792A3 - Compositions and methods for transdermal drug delivery - Google Patents
Compositions and methods for transdermal drug delivery Download PDFInfo
- Publication number
- WO1994017792A3 WO1994017792A3 PCT/US1994/000896 US9400896W WO9417792A3 WO 1994017792 A3 WO1994017792 A3 WO 1994017792A3 US 9400896 W US9400896 W US 9400896W WO 9417792 A3 WO9417792 A3 WO 9417792A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- compositions
- drug delivery
- transdermal drug
- iontophoresis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU67647/94A AU6764794A (en) | 1993-01-27 | 1994-01-26 | Compositions and methods for transdermal drug delivery |
JP6518085A JPH08510720A (en) | 1993-01-27 | 1994-01-26 | Compositions and methods for transdermal drug delivery |
EP94915749A EP0683668A4 (en) | 1993-01-27 | 1994-01-26 | Compositions and methods for transdermal drug delivery. |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US946393A | 1993-01-27 | 1993-01-27 | |
US08/009,463 | 1993-01-27 | ||
US7729693A | 1993-06-14 | 1993-06-14 | |
US7778693A | 1993-06-14 | 1993-06-14 | |
US08/077,786 | 1993-06-14 | ||
US08/077,296 | 1993-06-14 | ||
US10732993A | 1993-08-16 | 1993-08-16 | |
US08/107,329 | 1993-08-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994017792A2 WO1994017792A2 (en) | 1994-08-18 |
WO1994017792A3 true WO1994017792A3 (en) | 1994-09-29 |
Family
ID=27485882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/000896 WO1994017792A2 (en) | 1993-01-27 | 1994-01-26 | Compositions and methods for transdermal drug delivery |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0683668A4 (en) |
JP (1) | JPH08510720A (en) |
AU (1) | AU6764794A (en) |
CA (1) | CA2153243A1 (en) |
WO (1) | WO1994017792A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6348449B1 (en) * | 1993-09-21 | 2002-02-19 | The Trustees Of The University Of Pennsylvania | Methods of inducing mucosal immunity |
US5942395A (en) * | 1997-05-09 | 1999-08-24 | Universite De Montreal | Hybrid ribozymes and methods of use |
DE19814257A1 (en) * | 1998-03-31 | 1999-10-07 | Asta Medica Ag | effervescent formulations |
KR20010106462A (en) * | 1998-09-01 | 2001-11-29 | 체에베체 그레고르 | Electrically controlled transport of charged penetrants across barriers |
AU2007280690C1 (en) | 2006-07-31 | 2012-08-23 | Curevac Gmbh | Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant |
US8530436B2 (en) | 2007-01-29 | 2013-09-10 | Transderm, Inc. | Methods and compositions for transdermal delivery of nucleotides |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
AU2009210266B2 (en) | 2008-01-31 | 2015-01-29 | CureVac SE | Nucleic acids comprising formula (NuGlXmGmGnNv)a and derivatives thereof as an immunostimulating agents/adjuvants |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
DK2449113T3 (en) | 2010-07-30 | 2016-01-11 | Curevac Ag | Complex formation of nucleic acids with the disulfide cross-linked cationic components for transfection and immunostimulation |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
AU2014310934B2 (en) | 2013-08-21 | 2019-09-12 | CureVac SE | Respiratory syncytial virus (RSV) vaccine |
US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5042975A (en) * | 1986-07-25 | 1991-08-27 | Rutgers, The State University Of New Jersey | Iontotherapeutic device and process and iontotherapeutic unit dose |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU609769B2 (en) * | 1987-02-10 | 1991-05-09 | Drug Delivery Systems Inc. | Electrolytic transdermal delivery of proteins |
US5085749A (en) * | 1989-03-14 | 1992-02-04 | Massachusetts Institute Of Technology | Dynamically controlled membrane |
WO1990012022A1 (en) * | 1989-03-31 | 1990-10-18 | University Patents, Inc. | Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections |
US5248670A (en) * | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
-
1994
- 1994-01-26 EP EP94915749A patent/EP0683668A4/en not_active Withdrawn
- 1994-01-26 AU AU67647/94A patent/AU6764794A/en not_active Abandoned
- 1994-01-26 CA CA002153243A patent/CA2153243A1/en not_active Abandoned
- 1994-01-26 WO PCT/US1994/000896 patent/WO1994017792A2/en not_active Application Discontinuation
- 1994-01-26 JP JP6518085A patent/JPH08510720A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5042975A (en) * | 1986-07-25 | 1991-08-27 | Rutgers, The State University Of New Jersey | Iontotherapeutic device and process and iontotherapeutic unit dose |
Non-Patent Citations (6)
Title |
---|
Journal of Controlled Release, Volume 7, issued 1988, A.K. BANGA et al., "Iontophoretic Delivery of Drugs: Fundamentals, Developments and Biomedical Applications", pages 1-24, see the entire document. * |
Nature, Volume 355, issued 06 February 1992, L.C. BOCK et al., "Selection of Single-Stranded DNA Molecules that Bind and Inhibit Human Thrombin", pages 564-566, see the entire document. * |
Pharmaceutical Research, Volume 9, No. 10 (Supplement), issued October 1992, R. VAN DER GEEST et al., "Iontophoresis: A Transdermal Delivery Strategy for Antisense Oligonucleotide Drugs?", page S-67, Abstract BIOTEC 2004, see entire Abstract. * |
Proceedings of the National Academy of Sciences, USA, Volume 84, issued November 1987, P.L. FELGNER et al., "Lipofection: A Highly Efficient, Lipid-Mediated DNA-Transfection Procedure", pages 7413-7417, see the entire document. * |
See also references of EP0683668A4 * |
The Journal of Infectious Diseases, Volume 154, No. 6, issued December 1986, L.P. GANGAROSA, Sr. et al., "Iontophoresis of Vidarabine Monophosphate for Herpes Orolabialis", pages 930-934, see the entire document. * |
Also Published As
Publication number | Publication date |
---|---|
WO1994017792A2 (en) | 1994-08-18 |
EP0683668A4 (en) | 1997-12-29 |
AU6764794A (en) | 1994-08-29 |
JPH08510720A (en) | 1996-11-12 |
EP0683668A1 (en) | 1995-11-29 |
CA2153243A1 (en) | 1994-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9602656A (en) | Transdermal device containing polyvinylpyrrolidone as solubility enhancer. | |
PL330212A1 (en) | Preparation administered by transcutaneous absorption | |
AU4923500A (en) | Device and method for increasing the transdermal permeation of medicaments | |
WO1994017792A3 (en) | Compositions and methods for transdermal drug delivery | |
EP1234586A3 (en) | Hepatoselective pharmaceutical actives | |
AU4261097A (en) | Compositions and methods for topical application of therapeutic agents | |
AU2506388A (en) | Azelastine-containing medicaments for application in the nose and/or at the eye | |
AU6675198A (en) | Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use | |
WO2000038626A3 (en) | Substrate composition and method of use for sequestration of skin irritants | |
ATE288743T1 (en) | PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR ADMINISTRATION OF ACTIVE INGREDIENTS TO MUCOUS SKIN SURFACES | |
HUP9904023A2 (en) | Use of leptin antagonists for treating insulin resistance in type ii diabetes | |
EP0147146A3 (en) | Enhancement of transdermal drug delivery | |
EP0160501A3 (en) | Sustained release intranasal formulation and method of use thereof | |
AU7662400A (en) | Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin | |
EP0387693A3 (en) | Transdermal system with stepwise drug release, and its use in local or systemic cosmetic administration | |
ZA968905B (en) | Transdermal therapeutic system (tts) for administering active substances for drug dependence or drug addiction | |
ATE208200T1 (en) | TRANSDERMAL THERAPEUTIC SYSTEM (TTS) FOR ADMINISTRATION OF TESTOSTERONE | |
HUP9802897A3 (en) | Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient | |
EP0744176A3 (en) | Methods for inhibiting bone loss | |
EP0227531A3 (en) | Pyroglutamic acid esters used as dermal penetration enhancers for drugs | |
WO2002058532A3 (en) | Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof | |
WO1997017072A3 (en) | Use of flupirtin for the prevention and treatment of diseases which are associated with damage to the haemopoietic cell system | |
ZA987006B (en) | Transdermal therapeutic system (TTS) for delivering active ingredient through the skin to a body and method for application to the skin | |
BG103905A (en) | New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine | |
DE69431430T2 (en) | Factor XIII for the treatment of skin wounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP US US US US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP US US US US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2153243 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994915749 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1995 495490 Country of ref document: US Date of ref document: 19950926 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1994915749 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994915749 Country of ref document: EP |